Market Overview Uterine cancer is one such cancer that presently shows an increasing incidence and mortality in the United States. In North America, healthcare providers and community programs help women achieve and maintain a healthy weight and get enough physical activity, which can reduce the risk for endometrial cancer, the most common uterine cancer. Promoting awareness of the need for timely evaluation of abnormal vaginal bleeding (between periods, after sex, or after menopause), an important symptom of uterine cancer increases the chance for early detection and treatment.
Recent breakthroughs have led to many advances in personalized approaches to various cancer types, including cancers of the female reproductive system, like uterine cancer and endometrial cancer. Across entire North America, especially in the United States, in all the healthcare organizations, gynecologic oncologists are available to provide the common people with a second opinion and design a treatment plan tailored to the tumor type, cancer stage, and individual needs. Such initiatives have a positive impact on the uterine cancer treatment and diagnostics market in North America.
Scope of the Report Uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. Risk factors associated with this cancer are being overweight and starting periods at an early age.
Key Market Trends Immunotherapy to Register Highest CAGR Over the Forecast Period
Immunotherapy is a type of treatment, in which drugs help an individual’s immune system to recognize the cancer cells and kill them. Immunotherapy is done for treating certain forms of endometrial cancer that has spread or recurred. Pembrolizumab (Keytruda) by Merck and Co. is a drug that is used for the immunotherapy. This drug had got the FDA approval in June 2018, and it is currently available in the market. This drug is given as an intravenous (IV) infusion every 3 weeks. Currently, there are several ongoing clinical trials meant for examining different drugs and their combinations in uterine cancer, including a combination of two immunotherapies, such as lenvatinib (Lenvima) and pembrolizumab.
Some types of immunotherapy include monoclonal antibodies and tumor-agnostic therapies, non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines. However, among these types, only tumor-agnostic therapy is used. As the number of uterine cancer cases is increasing, companies are focusing more on producing novel drugs for immunotherapy. Therefore, it is expected that the use of immunotherapy may grow in the coming future. Thus, this may positively affect the overall market for uterine cancer treatment.
Competitive Landscape The uterine cancer diagnostics and treatment market is comprised of the global players that are having a focus on oncology division. Some of the major companies in this market include Merck & Co. Ltd, Pfizer Inc., AbbVie Inc., among others. With the rising research by the pharmaceutical industry on the development of better therapeutics and diagnostics for various cancers, more companies are believed to enter the market in the coming future.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - Report customization as per the client’s requirements - 3 months of analyst support
Our reports have been used by over 10K customers, including:
The global cancer cachexia market was valued at USD 2,256.35 million in 2020, and it is expected to reach USD 2,974.49 million by 2026, registering a CAGR of 4.47% during the forecast period. The outbreak of COVID-19 impacted the cancer cachexia market, as hospitals and healthcare services were significantly reduced due to social distancing...
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and rise in the reimbursement policies and funding for apheresis procedures. With the increasing...
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...
Nanoscale technology is widely used in medical devices and medicine where manipulations are made at the molecular level, taking advantage of the novel properties of a material. The primary demand of this field in medicine is in making improvements in the delivery of treatments and healthcare outcomes. Nanomedicine refers to the usage of nanoscale...
Ewing Sarcoma - Pipeline Review, H2 2020
latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2020, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.
Ewing’s sarcoma is a primary bone cancer that affects mainly...
Gallbladder Cancer - Pipeline Review, H2 2020
latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2020, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.
Gallbladder cancer is a cancer that starts in...
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
In Vitro Diagnostics
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.